If you've been told you have PCOS, you may soon hear a different name: PMOS (Polyendocrine Metabolic Ovarian Syndrome). The name change isn't just semantics. It reflects what researchers and clinicians have suspected for a while: this condition is more metabolic than it is ovarian, and the ovarian symptoms are downstream of something else entirely.
That something else, according to a review just published in the Journal of Clinical Investigation, is likely your gut hormones, specifically GLP-1 and GIP.
GLP-1 and GIP
GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are incretin hormones produced in the gut in response to eating. Their jobs include triggering insulin release, slowing gastric emptying, and regulating appetite. When they're working properly, blood sugar is stable, insulin stays in check, and your appetite signals are accurate.
In women with PMOS, these hormones are not working properly.
The JCI review found that altered secretion and function of GLP-1 and GIP are key contributors to both the metabolic and reproductive dysfunctions seen in PMOS. That includes insulin resistance, weight gain that won't respond to usual interventions, irregular cycles, and elevated androgens. The researchers also identified shared genetic risk loci between PMOS, obesity, and type 2 diabetes at the GIPR and GLP-1R genes. The genetic underpinning of PMOS runs through the same receptor genes that control these gut hormones. That's not something you can dismiss.
Why This Matters Clinically
I've been less interested in the conventional framing of PCOS as primarily an ovarian condition, and more interested in it as a metabolic syndrome with reproductive consequences. When gut hormone signaling is impaired, insulin goes up. Elevated insulin drives androgen production. Elevated androgens disrupt ovulation. The ovaries are reacting to a metabolic environment they didn't create.
I've written before about GLP-1 in the context of semaglutide. The reason GLP-1 receptor agonists show benefit in PMOS isn't simply because they cause weight loss. It's because they're restoring a hormone signal the gut wasn't producing adequately. The research shows improvements in ovarian cyclicity, insulin resistance, BMI, and waist circumference. Not because the drug is targeting the ovaries. Because the actual mechanism is being addressed.
This is also why metformin has been the standard medication for PCOS for decades, even though it's a diabetes drug. It improves insulin sensitivity. That's the point. The ovaries were never the primary problem.
Where to Start
If you have PMOS, your workup should go well beyond an ultrasound and a progesterone level. I want to know your fasting insulin, your post-meal glucose, your full hormone panel, and a complete picture of how your body is handling food.
GLP-1 and GIP don't work in isolation. They're part of a gut-metabolic chain connecting what you eat, how your gut processes it, how your pancreas responds, and what your reproductive hormones do downstream. Treating PMOS without addressing that chain is symptom management, nothing more.
The name changed for a reason. Start asking metabolic questions.